🇺🇸 Zunveyl in United States

FDA authorised Zunveyl on 26 July 2024

Marketing authorisations

FDA — authorised 26 July 2024

  • Application: NDA218549
  • Marketing authorisation holder: ALPHA COGNITION
  • Local brand name: ZUNVEYL
  • Indication: TABLET, DELAYED RELEASE — ORAL
  • Status: approved

The FDA approved Zunveyl, a new active ingredient in a new dosage form, for the treatment of a specific condition. The approval was granted to ALPHA COGNITION, the marketing authorisation holder. The approval date was 26 July 2024, and the application number was NDA218549.

Read official source →

FDA

  • Marketing authorisation holder: ALPHA COGNITION
  • Status: approved

Zunveyl in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in United States

Frequently asked questions

Is Zunveyl approved in United States?

Yes. FDA authorised it on 26 July 2024; FDA has authorised it.

Who is the marketing authorisation holder for Zunveyl in United States?

ALPHA COGNITION holds the US marketing authorisation.